Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Pedro, Isaacsson Velho"'
Autor:
Rodolfo Borges dos Reis MD, PHD, José L. Aguilar-Ponce MD, Federico Cayol MD, MSc, Angela M. Jansen PhD, MHS, Ray Manneh K MD, MSc, Tomas R Merino MD, Gayatri Sanku PhD, MPH, Laura B. Vaca MD, Pedro Isaacsson Velho MD, Ernesto P. Korbenfeld MD
Publikováno v:
Cancer Control, Vol 31 (2024)
In Latin America, prostate cancer is the third most common cancer overall and the most common in men, with the highest mortality rate of all cancers. In 2022, there were approximately 22,985 new prostate cancer cases and 61,056 deaths from prostate c
Externí odkaz:
https://doaj.org/article/02d40ef4d4894cab8a0974095637a926
Autor:
Jeziel Basso, Juliana Beust de Lima, Marina Bessel, Santiago Alonso Tobar Leitão, Thais Machado Baptista, Sergio Roithmann, Eduardo Franco Carvalhal, Caio da Silva Schmitt, Ivan Morzoletto Pedrollo, Alice Schuch, Antonio Atalibio Hartmann, Carmen Liane Neubarth Estivallet, Guilherme Behrend Silva Ribeiro, Ricardo Andre Zordan, Pedro Isaacsson Velho
Publikováno v:
BMC Urology, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background Prostate cancer exhibits a very diverse behaviour, with some patients dying from the disease and others never needing treatment. Active surveillance (AS) consists of periodic PSA assessment (prostate-specific antigen), DRE (digita
Externí odkaz:
https://doaj.org/article/019a1eb681324b1db305473aaa9cb4dc
Autor:
Nima Nabavi, Seied Rabi Mahdavi, Mohammad Afshar Ardalan, Mohsen Chamanara, Reza Mosaed, Aline Lara, Diogo Bastos, Sara Harsini, Emran Askari, Pedro Isaacsson Velho, Hamed Bagheri
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 2084 (2023)
Androgen deprivation therapy (ADT) remains the cornerstone of advanced prostate cancer treatment. However, the progression towards castration-resistant prostate cancer is inevitable, as the cancer cells reactivate androgen receptor signaling and adap
Externí odkaz:
https://doaj.org/article/5aa20dcaf14041718ded79d4ccf09c1e
Autor:
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Albert Jang, Pedro Barata, Guru Sonpavde, Evan Y. Yu, Robert Bruce Montgomery, Petros Grivas, Ali Raza Khaki
Publikováno v:
Clin Genitourin Cancer
Clinical genitourinary cancer, vol 20, iss 5
Clinical genitourinary cancer, vol 20, iss 5
Immune checkpoint inhibitors are a well-established treatment option for advanced urothelial carcinoma, and biomarkers of response are needed for better patient selection. We show that metastatic disease confined to lymph nodes is associated with bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e21730b8ba4dde650e4272d84696a24
https://doi.org/10.1016/j.clgc.2022.06.001
https://doi.org/10.1016/j.clgc.2022.06.001
Autor:
Aline B.L. Gongora, Catherine H Marshall, Pedro Isaacsson Velho, Carlos D.H. Lopes, José F. Marin, Anamaria A. Camargo, Diogo A. Bastos, Emmanuel S. Antonarakis
Publikováno v:
Clinical Genitourinary Cancer. 20:183-188
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17b4f85418096fb053c27770c05e65a9
https://doi.org/10.1016/j.clgc.2021.11.015
https://doi.org/10.1016/j.clgc.2021.11.015
Autor:
Pedro Isaacsson Velho, Mirella Nardo, Manoel Carlos Leonardi de Azevedo Souza, Renata R.C. Colombo Bonadio, Guilherme Nader Marta, David Q.B. Muniz, Diogo Assed Bastos, Carlos Dzik
Publikováno v:
Journal of Global Oncology, Vol 4 (2018)
Purpose: Sunitinib and pazopanib are multitargeted tyrosine kinase inhibitors (TKIs) that act against vascular endothelial growth factor receptors and are standard first-line treatment options for metastatic clear cell renal cell carcinoma (ccRCC). T
Externí odkaz:
https://doaj.org/article/f3c9c17cfeda46e9aa4b0d55cb12de9f
Autor:
Pedro Isaacsson Velho, Mike Fang, Mari Nakazawa, Tamara L. Lotan, Catherine Handy Marshall, Emmanuel S. Antonarakis
Publikováno v:
Prostate
Background Inactivating missense mutations in the SPOP gene, encoding speckle-type poxvirus and zinc-finger protein, are one of the most common genetic alterations in prostate cancer. Methods We retrospectively identified 72 consecutive prostate canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3228be330b4f0e31794f21e9f61fc185
https://doi.org/10.1002/pros.24269
https://doi.org/10.1002/pros.24269
Autor:
Jonathan L. Wright, Alexander Sankin, Petros Grivas, Ignacio Duran, Ali Raza Khaki, Dimitrios Makrakis, Pedro C. Barata, Guru Sonpavde, Benjamin A. Gartrell, Vadim S. Koshkin, Evan Shreck, Lucia Carril-Ajuria, David J. Pinato, Mehmet Asim Bilen, Neeraj Agarwal, Mark P. Lythgoe, Giuseppe Di Lorenzo, Jayanshu Jain, Daniel Castellano, Ivan de Kouchkovsky, Rana R. McKay, Jure Murgic, Tyler F. Stewart, Michael Edward Devitt, Rafee Talukder, Pedro Isaacsson-Velho, Sandy T. Liu, Rafael Morales-Barrera, Lucia Alonso Buznego, Marcus Marie Moses, Leonidas Nikolaos Diamantopoulos, Aristotelis Bamias, Joseph J. Park, Ana Fröbe, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Victor Sacristan Santos, Monika Joshi, Evan Y. Yu, Alejo Rodriguez-Vida, Michael Grant, Ajjai Alva, Christopher J. Hoimes, Abhishek Tripathi
Publikováno v:
BJU international, vol 130, iss 5
BJU Int
BJU Int
OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64617a8b9d10e6092cd0be747466efd
https://escholarship.org/uc/item/8678m8j9
https://escholarship.org/uc/item/8678m8j9
Autor:
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Tanya Jindal, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Guru Sonpavde, Jonathan L. Wright, Evan Y. Yu, Robert Bruce Montgomery, Andrew C. Hsieh, Petros Grivas, Ali Raza Khaki
Publikováno v:
Clin Genitourin Cancer
Clinical genitourinary cancer, vol 20, iss 6
Clinical genitourinary cancer, vol 20, iss 6
Immune checkpoint inhibitors improve overall survival in advanced urothelial carcinoma, but response rates remain modest. We performed a multi-institutional retrospective cohort study comparing outcomes (observed response rate, progression-free, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::838aa9eb8a9455bbff00b10cd1e01eda
https://europepmc.org/articles/PMC10233855/
https://europepmc.org/articles/PMC10233855/
Autor:
Srinivasan Yegnasubramanian, Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Su Jin Lim, Emily Nizialek, Hao Wang
Publikováno v:
The Prostate. 81:572-579
BACKGROUND Clinical outcomes may differ among patients presenting with primary (de novo) metastatic hormone-sensitive prostate cancer (mHSPC) versus secondary (metachronous) mHSPC occurring after local therapy. It is unknown what molecular features d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4056d025e2e536f3801ec3df35405b72
https://doi.org/10.1002/pros.24135
https://doi.org/10.1002/pros.24135